Page 4 - Andy Chen News Today

(Reuters) - A panel of independent experts to the U.S. health regulator urged Acrotech Biopharma to work with the agency to bring forward the date for...

Robert Califf’s all-hands email to FDA staff came hours after POLITICO first reported the news of Woodcock’s retirement plans.

The consensus of the advisory committee is that we have significant concerns about the very prolonged delay and getting these confirmatory studies underway.

No easy answers for two drugs for rare lymphoma on long cruise with accelerated approval

A panel of independent experts to the U.S. health regulator urged Acrotech Biopharma to work with the agency to bring forward the date for releasing trial data that could confirm benefits of the...

The drugs, Folotyn and Beleodaq, have already been on the market for nearly a decade or more. "We would like the FDA and sponsor to strategize about other possible ways to have a shorter study readout than waiting another seven years from now," the panel's acting chairperson Andy Chen said on Thursday. The company's final study plan was submitted to the FDA in 2022 and is expected to be completed by 2030, according to FDA briefing documents published earlier this week.

/PRNewswire/ -- DL Holdings Group Limited ("DL Holdings" or the "Company", together with its subsidiaries, the "Group", Stock Code: 1709.HK) issued a voluntary...

At this years China International Import Expo (CIIE), Taiwan-based Yoshantea Tea Co has used 6,000 cups, offering tea from the island for guests to taste. The bustling presence of Taiwan entrepreneurs shows their eagerness to seize the opportunity to ride on the fast-paced development of the Chinese mainlands economy amid the policy dividends offered by the mainland.

The Walking Dead’s Chandler Riggs will play Peter Parker in an upcoming Spider-Man horror movie

With Class III designation, sponsors would have to prove safety, efficacy with randomized trials